

Novartis to focus on higher-margin drugs

New Novartis Chief Executive Vas Narasimhan has announced that the company is selling U.S. dermatology and generic pill assets to India's Aurobindo Pharma Ltd for up to USD 1 billion. The deal, which comes after price pressure hurt the U.S. pills business, includes some 300 products.